Immunology and Microbiology
Asthma
100%
Severe Asthma
89%
Airway
75%
Human Respiratory Syncytial Virus
62%
Comorbidity
46%
Mepolizumab
41%
Omalizumab
41%
Neutrophil
41%
Allergic Asthma
41%
Substance P
41%
Respiratory Syncytial Virus Infection
40%
Endosome
27%
Bronchiolitis
26%
Angiogenesis
25%
Mycoplasma pulmonis
24%
Blood Plasma
24%
Prevalence
22%
Cell Adhesion Proteins
20%
Alveolar Macrophage
20%
Granulocyte
20%
Tumor Necrosis Factor Alpha
20%
Internalization
20%
Trachea Mucosa
20%
Programmed Cell Death
20%
L-Selectin
20%
Platelet Endothelial Cell Adhesion Molecule 1
20%
Histamine
20%
Neurogenic Inflammation
20%
Dexamethasone
20%
Hypersensitivity
20%
Upregulation
20%
Major Histocompatibility Complex
16%
Immunoglobulin E
14%
Capillary
13%
Venule
13%
Cadherin
12%
Blood Vessel
12%
Disease Burden
10%
Respiratory Mucosa
10%
Fischer 344 Rat
8%
Intercellular Adhesion Molecule 1
8%
CD18
7%
Ligand Binding
6%
Eosinophil
6%
Mediator
6%
Forced Expiratory Volume
6%
Sensitization
6%
Leukocyte Adherence
5%
Particulate Matter
5%
Immune Response
5%
Medicine and Dentistry
Asthma
94%
Severe Asthma
82%
Non Small Cell Lung Cancer
62%
Chemoradiotherapy
41%
Smoke
41%
Epidermal Growth Factor Receptor
41%
Pleura Effusion
41%
Omalizumab
41%
Mepolizumab
41%
Lung
28%
Lung Cancer
23%
Randomized Controlled Trial
23%
Obstructive Sleep Apnea
22%
Neurokinin 1 Receptor
20%
Respiratory Tract Inflammation
20%
Biological Product
20%
Pulmonary Edema
20%
Patient with Asthma
20%
Cost-Effectiveness Analysis
20%
Nurse
20%
Systematic Review
20%
Chronic Obstructive Pulmonary Disease
20%
Hypersensitivity
20%
Pleural Disease
20%
Angiogenesis
20%
Upregulation
20%
Table Salt
20%
Pneumothorax
20%
Anxiety Disorder
20%
Substance P
20%
Epidermal Growth Factor Receptor Kinase Inhibitor
20%
Asthma Control Questionnaire
17%
Overall Survival
17%
Surgery
17%
Eosinophilic
16%
Endosome
14%
Receptor Gene
14%
Particular Matter 2.5
13%
Recurrent Disease
13%
Progression Free Survival
13%
Diseases
12%
Endothelial Cell
11%
Capillary
11%
Spontaneous Remission
10%
Non-Small Cell Lung Cancer
10%
Bronchodilating Agent
10%
Comorbidity
10%
Clinical Assessment
9%
Body Mass Index
9%
Polysomnography
8%
Pharmacology, Toxicology and Pharmaceutical Science
Substance P
70%
Asthma
49%
Formoterol
41%
Mepolizumab
41%
Adrenergic Receptor Stimulating Agent
27%
Receptor
24%
Mycoplasma pulmonis
23%
Neurokinin 1 Receptor
23%
Pneumothorax
20%
Chemoradiation Therapy
20%
Infection
20%
Omalizumab
20%
Epidermal Growth Factor Receptor Kinase Inhibitor
20%
Neurogenic Inflammation
20%
Normal Human
20%
Pleura Effusion
20%
Table Salt
20%
Remission
20%
Oxytetracycline
20%
Respiratory Tract Inflammation
20%
Lung Edema
20%
Non Small Cell Lung Cancer
20%
Opiate
20%
Dexamethasone
20%
Biological Product
20%
Gonadorelin
20%
Overall Survival
17%
Fischer 344 Rat
13%
Luteinizing Hormone
8%
Extravasation
8%
Diseases
8%
Methacholine
8%
Antibiotics
8%
Respiratory Tract Disease
8%
Antiinflammatory Agent
8%
Osimertinib
6%
Progression Free Survival
6%
Survival Rate
6%
Infectious Agent
6%
Naloxone
5%
Bradykinin
5%
Adrenergic Receptor
5%
Inflammation
5%
